The current state of evidence for sodium and fluid restriction in heart failure.
Prog Cardiovasc Dis
; 82: 43-54, 2024.
Article
de En
| MEDLINE
| ID: mdl-38215917
ABSTRACT
The field of heart failure has evolved in terms of the therapies that are available including pharmaceutical and device therapies. There is now substantial randomized trial data to indicate that dietary sodium restriction does not provide the reduction in clinical events with accepted heterogeneity in the clinical trial results. Dietary sodium restriction should be considered for some but not all patients and with different objectives than clinical outcomes but instead for potential quality of life benefit. In addition, fluid restriction, once the mainstay of clinical practice, has not shown to be of any additional benefit for patients in hospital or in the ambulatory care setting and therefore should be considered to be used cautiously (if at all) in clinical practice. Further developments and clinical trials are needed in this area to better identify patients who may benefit or have harm from these lower cost interventions and future research should focus on large scale, high quality, clinical trials rather than observational data to drive clinical practice.
Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Sodium alimentaire
/
Défaillance cardiaque
Type d'étude:
Clinical_trials
Aspects:
Patient_preference
Limites:
Humans
Langue:
En
Journal:
Prog Cardiovasc Dis
Année:
2024
Type de document:
Article
Pays d'affiliation:
Mexique
Pays de publication:
États-Unis d'Amérique